An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)
Phase 3
Withdrawn
- Conditions
- Systemic Juvenile Idiopathic Arthritis
- Interventions
- First Posted Date
- 2012-08-31
- Last Posted Date
- 2015-10-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT01676948
Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism
- First Posted Date
- 2012-08-28
- Last Posted Date
- 2019-09-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 33
- Registration Number
- NCT01673646
- Locations
- 🇯🇵
Novartis Investigative Site, Yamagata, Japan
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD) With Cachexia
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-08-20
- Last Posted Date
- 2016-05-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 67
- Registration Number
- NCT01669174
- Locations
- 🇬🇧
Novartis Investigative Site, Machester, United Kingdom
Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
Phase 3
Completed
- Conditions
- Secondary Progressive Multiple Sclerosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-08-15
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1651
- Registration Number
- NCT01665144
- Locations
- 🇬🇧
Novartis Investigative Site, Newcastle Upon Tyne, United Kingdom
Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to Amlodipine
Phase 3
Completed
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2012-08-13
- Last Posted Date
- 2015-10-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 266
- Registration Number
- NCT01663233
- Locations
- 🇨🇳
Novartis Investigative Site, Taipei, Taiwan
Pharmacokinetics of Certoparin in Subjects With Renal Insufficiency and Healthy Subjects
Phase 1
Completed
- Conditions
- Renal Insufficiency
- Interventions
- First Posted Date
- 2012-08-08
- Last Posted Date
- 2012-08-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT01660295
- Locations
- 🇭🇺
DRC Drug Research Center Ltd., H-8230 Balatonfüred, H-8230 Balatonfüred, Ady E. u., Hungary
BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.
Phase 2
Completed
- Conditions
- Pancreatic Neuroendocrine Tumors (pNET)
- Interventions
- Drug: BEZ235 (Stage 1)
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2016-05-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT01658436
- Locations
- 🇺🇸
Indiana University SC, Indianapolis, Indiana, United States
🇺🇸Dana Farber Cancer Institute GastrointestionalCancer Clinic, Boston, Massachusetts, United States
🇺🇸Montefiore Medical Center SC-2, Bronx, New York, United States
A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell Carcinoma
Phase 1
Completed
- Conditions
- Metastatic Melanoma and Merkel Cell Carcinoma
- Interventions
- First Posted Date
- 2012-07-30
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 10
- Registration Number
- NCT01652547
- Locations
- 🇨🇭
Novartis Investigative Site, Zuerich, Switzerland
Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma
- First Posted Date
- 2012-07-25
- Last Posted Date
- 2020-07-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 662
- Registration Number
- NCT01649778
- Locations
- 🇬🇧
Novartis Investigative Site, Shrewsbury, United Kingdom
16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis
Phase 3
Completed
- Conditions
- Anklyosing Spondylitis
- Interventions
- First Posted Date
- 2012-07-25
- Last Posted Date
- 2019-10-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 219
- Registration Number
- NCT01649375
- Locations
- 🇬🇧
Novartis Investigative Site, Torquay, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath